[A18-58] Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V
Last updated 02.01.2019
Project no.:
A18-58
Commission:
Commission awarded on 24.09.2018 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Airways and respiratory system, Children's and adolescents' health
Add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older
Added benefit not proven due to lack of suitable data
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-03 | Mepolizumab - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-151 | Mepolizumab (eosinophilic granulomatosis with polyangiitis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-152 | Mepolizumab (hypereosinophilic syndrome) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A21-150 | Mepolizumab (chronic rhinosinusitis with nasal polyposis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-03-22 A G-BA decision was published.